Your browser doesn't support javascript.
loading
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner, C N; Castro, C; Penson, R T; Roche, M; Matulonis, U A; Morgan, M A; Drescher, C; Armstrong, D K; Wolfe, J K; Lee, H; Supko, J G; Seiden, M; Birrer, M J; Dizon, D S.
Afiliación
  • Krasner CN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America. Electronic address: Carolyn_krasner@dfci.harvard.edu.
  • Castro C; Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Penson RT; Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Roche M; Blueprint Bio, Cambridge, MA, United States of America. Electronic address: mroche2@blueprintmedicines.com.
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Morgan MA; Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: Mark.Morgan@uphs.upenn.edu.
  • Drescher C; Translational Research Program, Division of Gynecologic Oncology, Fred Hutchinson Cancer Center, Seattle, WA, United States of America. Electronic address: cdresche@fredhutch.org.
  • Armstrong DK; Department of Medical Oncology, Johns Hopkins University Medical Center, Baltimore, MD, United States of America. Electronic address: armstde@jhmi.edu.
  • Wolfe JK; Community Health, Indianapolis, IN, United States of America. Electronic address: JWolf4@ecommunity.com.
  • Lee H; Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Supko JG; Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Seiden M; US Oncology, United States of America. Electronic address: Michael.seiden@mckesson.com.
  • Birrer MJ; Department of Medical Oncology, University of Alabama, Birmingham, AL, United States of America. Electronic address: mbirrer@uab.edu.
  • Dizon DS; Department of Medical Oncology, Rhode Island Hospital, United States of America. Electronic address: don.dizon@lifespan.org.
Gynecol Oncol ; 153(2): 223-229, 2019 05.
Article en En | MEDLINE | ID: mdl-30765148
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Epitelial de Ovario Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Epitelial de Ovario Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos